Subject: Major New Player in Massive Medical Markets SNWV

SCV Client Spotlight SNWV Logo
SNWV Surging As FDA Approved Phase-3 Clinical Trials Begin

SANUWAVE Health Inc
11475 Great Oaks Way, Suite 150
Alpharetta, GA 30022
Phone: (866) 581-6843
sanuwave.com

PROFILE:

SANUWAVE Health, Inc. is an emerging leader in the development and commercialization of noninvasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures.

SANUWAVE’s portfolio of products and product candidates activate biologic signaling and angiogenic responses, including revascularization and microcirculatory improvement, helping restore the body’s normal healing processes and regeneration. SANUWAVE is applying its Pulsed Acoustic Cellular Expression (PACE) technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions.

Headquartered in Alpharetta, GA, SANUWAVE designs, manufactures, markets, and services its industry leading products worldwide.

VALUE PROPOSITION:
SNWV


Increased Growth Opportunities

  • Expand global distribution of current products.
  • Expand technology platform in non-medical industries.

Improved Strategy, Focus, and Execution

  • Senior management changes - added experience and focus in critical areas.

Excellent Cap Structure

  • Very tightly held company with small public float

Competitive Landscape

  • Currently there is NO direct competitor to the dermaPace.

Over 54M Dollars Has been invested in this shock wave technology since 2005

  • For those concerned that this Company is a start up, dermaPACE® for advanced wound care was launched in 2007.

Intellectual Property Portfolio

  • Portfolio covers various methods and devices for treating a range of conditions using acoustic pressure waves in the high-energy “shock wave” spectrum.
  • 17 issued U.S. patents.
  • 7 U.S. patents pending.
  • 9 issued or pending foreign patents.

SNWV has extensive experience and applied understanding of the number of pulses, energy settings, and frequency required to effect.

dermaPACE - Treatment Advantages

Offers a significant advance in the treatment of diabetic foot ulcers.

ADVANTAGES

  • Lowest total treatment costs.
  • Significantly lower recurrence rates.
  • Convenient and efficient treatments.
  • Non-invasive.

dermaPACE - U.S. Market Opportunity

Diabetic Foot Ulcers - 5B+ Dollars

  • 27 million persons living with diabetes and 79 million pre-diabetics.
  • 25% of diabetics will acquire a non-healing ulcer in their lifetime; ~1.5+ million diabetic ulcers annually.
  • Diabetic foot ulcers (DFUs) lead to over 82,000 amputations annually at a cost that are estimated to exceed 3.6 billion dollars annually.
  • Hospitalization costs of ~20,000 dollars for a patient with a DFU; ~60,000 dollars for an amputation.

dermaPACE - International Market

The international global wound care market of 22 billion dollars offers significant expansion opportunity for dermaPACE.

INTERNATIONAL MARKET

  • Globally there are 366 million people living with diabetes and it is expected to reach 552 million by 2030, an increase of 50.7%.
  • dermaPACE is currently marketed by independent distributors in Spain, Australia, Canada, and the Middle East.
  • dermaPACE can be licensed or joint ventured in these markets to speed market penetration while minimizing operating costs.
SNWV Chart

OTCBB: SNWV

Market Value:
17,372,331 dollars a/o Apr 04, 2013

Shares Outstanding:
21,580,536 a/o Mar 22, 2013

Shareholders of Record:
64 a/o Mar 26, 2013

Transfer Agent:
Action Stock Transfer Corporation

RECENT NEWS:

SANUWAVE Health Reports 2012 Financial Results and Provides Business Update

SANUWAVE Announces dermaPACE Regulatory Approval and Distribution Agreement in Australia and New Zealand

KEY EXECUTIVES:

Joseph Chiarelli

CEO

Barry J. Jenkins
CFO
COO

Peter Stegagno
Vice President, Operations

Iulian Cioanta, PhD

Vice President of
Research and Development

Joel Batts
Vice President of Clinical Affairs


MEDICAL MARKET OPPORTUNITIES

Advanced Wound Care
Diabetic Foot Ulcer
Chronic Mixed Wounds
Pressure Sores
Burns

Cardiac/Vascular
Myocardial Ischemia
Peripheral Artery Disease
Artherosclerosis
Renal Nerve Ablation

Cleaning and Sterilization
Blood
Tissue
Graft
Organ

Orthopedics
Trauma/Fracture
Osteoporosis
Osteoarthritis
Tendon/Pain
Spine

Tissue Regeneration
Nerve Regeneration
Stem Cells Proliferation
Tissue Regeneration
Organ Regeneration

Plastic/Cosmetic
Body Contouring
Scar Modulation
Varicose Veins
Spider Veins

Like Us on FacebookFollow Us on Twitter

IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks